Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to…
Role of CathWorks FFRangio for the Assessment of Coronary Artery Disease Now Reinforced by SCAI Expert Opinion
NEWPORT BEACH, Calif., Feb. 3, 2026 /PRNewswire/ -- CathWorks, a global leader…
